Shots:

• Iktos will leverage its de novo generative design technology to be used in a structure-enabled context- facilitating the rapid & cost-effective design of Merck KGaA’s drug discovery program
• The collaboration follows the previous agreement of the companies signed in 2019. Merck KGaA is utilizing Iktos’ de novo design software platform Makya for MPO
• Iktos’ AI technology is based on deep generative models that help bring speed & efficiency to the drug discovery process by automatically designing virtual novel molecules having desired activities for treating a disease

  Ref: Businesswire | Image: Merck KGaA